(NASDAQ: OBIO) Orchestra Biomed Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.76%.
Orchestra Biomed Holdings's earnings in 2025 is -$75,101,000.On average, 9 Wall Street analysts forecast OBIO's earnings for 2025 to be -$100,902,474, with the lowest OBIO earnings forecast at -$98,497,077, and the highest OBIO earnings forecast at -$102,568,184. On average, 9 Wall Street analysts forecast OBIO's earnings for 2026 to be -$90,134,650, with the lowest OBIO earnings forecast at -$90,750,116, and the highest OBIO earnings forecast at -$85,967,553.
In 2027, OBIO is forecast to generate -$66,233,129 in earnings, with the lowest earnings forecast at -$66,955,878 and the highest earnings forecast at -$61,066,607.